Table 2.
Real-world nivolumab treatment patterns
| Factor | |
|---|---|
| Patients, N | 208 |
| Number of doses, median (range) | 12 (1–47) |
| Duration of treatment (months), median (range) | 6.3 (0.0–24.7) |
| Treatment linea, n (%) | |
| 1st | 2 (1.0) |
| 2nd | 76 (36.5) |
| 3rd | 64 (30.8) |
| ≥ 4th | 66 (31.7) |
| Ongoing treatment, n (%) | 56 (26.9) |
| Discontinuation of treatment, n (%) | 152 (73.1) |
| Reason for discontinuation of treatmentb, n (%) | |
| Progression of mRCC | 100 (65.8) |
| AE and/or ADR | 43 (28.3) |
| Discontinuation after confirming efficacy | 1 (0.7) |
| Patient request | 10 (6.6) |
| Death | 9 (5.9) |
| Status immediately before nivolumab therapyc | |
| Classification, therapeutic drugs, n (%) | |
| VEGFR-TKI | 188 (90.4) |
| mTORi | 13 (6.3) |
| Cytokine | 2 (1.0) |
| Others | 3 (1.4) |
| Status immediately after nivolumab therapy | |
| Classification, therapeutic drugs, n (%) | |
| VEGFR-TKI | 65 (31.3) |
| mTORi | 8 (3.8) |
| Cytokine | 0 (0.0) |
| Others | 0 (0.0) |
| No treatment | 135 (64.9) |
| Ongoing nivolumab | 56 (41.5) |
| No treatment after nivolumab therapy | 79 (58.5) |
ADR adverse drug reaction, AE adverse event, mTORi mammalian target of rapamycin inhibitor, mRCC metastatic renal cell carcinoma, VEGFR-TKI vascular endothelial growth factor receptor-tyrosine kinase inhibitor
aAll patients received TKI as perioperative treatment
bMultiple answers were allowed
cIncluded patients who received nivolumab as second- or later line of therapy